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The process of identifying and developing 
molecules with useful bioactive properties, 
such as pharmaceutical agents, pesticides and 
food additives, is fraught with difficulty. In 
the pharmaceutical industry only a very small 
percentage of investigational new drugs will 
make it through to approved clinical usage, 
for reasons that include lack of efficacy,  
unexpected side effects and toxicity, and 
undesirable drug–drug interactions. Active 
pesticides that have undesirable side effects 
against organisms other than their original 
target will also not make it to the market. 
Food additives such as plant sterols are  
subject to strict regulations on their safety and 
possible off-target effects.
Published reports on the properties of 
‘failed’ molecules, in addition to detailed 
information on those that become fully 
licensed and commercially available, are 
crucial for developing an understanding  
of how improved molecules may be  
developed. Details of the molecular  
structure and mechanism of action of 
molecules may give clues as to how related 
analogues could be developed that modu-
late the same target, but with improved 
effectiveness or increased specificity. A 
full disclosure of observed toxicity or an 
understanding of the pharmacokinetic 
properties of an agent may help to improve 
these properties in subsequent generations 
of molecules. Even those molecules that fail 
at an early stage in the development process 
may be useful as tools; for example, in aid-
ing the validation of potential new targets 
that are identified through genomic and/or 
proteomic studies of disease.
Another area in which integrating  
knowledge on bioactive entities could be 
valuable is in identifying proteins that could 
be amenable to modulation by small mol-
ecules. In 2002, Hopkins and Groom1 intro-
duced the concept of the ‘druggable genome’ 
to describe the portion of the human 
genome that encoded proteins that were 
both linked to disease and were tractable 
targets for small-molecule drugs. Since then, 
progress has been made with computational 
approaches to calculate the druggability of 
proteins and to predict druggable proteins2–5. 
In 2006, Overington et al.6 estimated that 
the number of protein targets for approved 
drugs at the time was as low as 266 out of the 
20,400 protein-coding genes7 in the human 
genome (a further 58 targets were either 
from pathogenic organisms or they were 
non-protein molecules). Similar models 
may be developed to assess the susceptibility 
of proteins encoded by plant or microbial 
genomes to modulation by small molecules. 
Mining computationally accessible resources 
of data on bioactive entities could provide 
synergistic benefits for research and devel-
opment across the fields of drug discovery, 
pesticide science, cosmetics, nutraceuticals, 
metabolomics and toxicology.
At present, however, much of the substan-
tial volume of data that would aid predictions 
of protein targets that could be successfully 
modulated, and the development of new or 
improved molecules to modulate these tar-
gets, resides in proprietary databases. This is 
especially the case for agents that have subse-
quently failed at some stage of the discovery 
process (for example, owing to poor pharma-
cokinetics or toxicity). Nevertheless, owing to 
the current productivity crisis and decreasing 
budgets for early-stage research, the pharma-
ceutical, biotechnology and food industries 
are increasingly considering the precompeti-
tive release of compound-related bioactivity 
data into public repositories, recognizing that 
this could not only provide a general benefit 
for research but also a commercial advantage 
as data only need to be collected once. The 
manual curation of data is an expensive pro-
cess and requires resources that are often not 
available in even the largest pharmaceutical 
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Abstract | Bioactive molecules such as drugs, pesticides and food additives are 
produced in large numbers by many commercial and academic groups around the 
world. Enormous quantities of data are generated on the biological properties and 
quality of these molecules. Access to such data — both on licensed and 
commercially available compounds, and also on those that fail during development 
— is crucial for understanding how improved molecules could be developed. For 
example, computational analysis of aggregated data on molecules that are 
investigated in drug discovery programmes has led to a greater understanding of 
the properties of successful drugs. However, the information required to perform 
these analyses is rarely published, and when it is made available it is often missing 
crucial data or is in a format that is inappropriate for efficient data-mining. Here, 
we propose a solution: the definition of reporting guidelines for bioactive entities 
— the Minimum Information About a Bioactive Entity (MIABE) — which has been 
developed by representatives of pharmaceutical companies, data resource 
providers and academic groups.
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companies. In addition, a single company 
has only a limited range of in-house products 
that target an equally restricted number of 
targets. By integrating knowledge from other 
commercial and academic groups, a broader 
understanding of the viability of a potential 
target protein may be reached before expen-
sive resources are committed to a research 
programme.
This precompetitive activity can also have 
wider benefits; for example, in academic or 
non-profit discovery and in the development 
of drugs for orphan and tropical diseases. 
A recent encouraging example has been the 
release of data by GlaxoSmithKline, Novartis 
and St Jude Children’s Research Hospital, 
USA, on over 14,000 compounds that are 
known to be active against the parasite that 
is responsible for transmitting malaria; 
these data are now available in the ChEMBL 
database. The same database was used in 
a chemogenomic screen that identified 
Schistosoma mansoni proteins against which 
existing drugs may be active, thus providing 
hope that known therapeutics could be used 
to treat the neglected tropical disease schis-
tosomiasis, which affects 210 million people 
in 76 countries8.
However, to fully understand the grow-
ing wealth of data on bioactive compounds, 
the context, methods, results, conclusions 
and detailed background information 
pertaining to experiments also need to be 
included. The diversity of experimental 
designs and analytical techniques is increas-
ing as new methods are being developed 
and the scale of data production is rising 
owing to the widespread application of 
automation. This makes the formal speci-
fication of these metadata — ‘data about 
the data’ — of increasing importance. By 
being associated with the results, these 
metadata make both the biological and 
methodological contexts of the experiment 
explicit. The archetype of such a specifica-
tion is the ‘Minimum Information about a 
Microarray Experiment’ (MIAME)9. Many 
journals and funding agencies now require 
authors reporting on microarray-based 
transcriptomics experiments to comply with 
the MIAME checklist as a prerequisite for 
publication. The adoption and development 
of such specifications has had a considerable 
impact beyond simply increasing the com-
prehension and comparability of journal 
articles, the most important aspect of which 
is facilitating the transfer of data from jour-
nal articles into databases (that is, convert-
ing unstructured data into structured data) 
in a form that enables data mining across 
combined data sets.
We therefore propose a new docu-
ment — the ‘Minimum Information About 
a Bioactive Entity’ (MIABE) — that is 
predominantly concerned with, but not 
restricted to, bioactive chemical compounds. 
We believe the timing of this is apposite 
for several reasons. The first reason is the 
ongoing revolution in databases that hold 
information on the bioactivity of small 
molecules. In particular, the embedding of 
the ‘missing entity’ of chemical structures 
in databases such as the Chemical Entities 
of Biological Interest (ChEBI) database10 
and the PubChem project11 during the past 
decade has made it possible to search across 
biological effects, protein names, sequence 
data and chemical information. New tech-
nologies have emerged that can be used to 
directly interconnect the data sets in differ-
ent types of databases, thereby improving the 
power of any search. Second, results from 
high-throughput screening, as well as other 
types of bioactivity screening data, that are 
directly linked to information on chemical 
structures are increasingly being deposited 
in public repositories such as the PubChem 
Bioassay11, ChemBank12 and ChEMBL data-
bases. Third, drug discovery and agricultural 
studies are no longer limited to the com-
mercial sector. Publicly funded initiatives 
such as the US National Institutes of Health’s 
Molecular Libraries Program, the Innovative 
Medicines Initiative and the European 
Union’s EU-Openscreen project aim to both 
enhance chemical biology efforts through 
high-throughput screening and speed up the 
development of better and safer medicines. 
The resulting data from these programmes 
belong in the public domain and it is in eve-
ryone’s interest to ensure that these data are 
made available in the most appropriate for-
mat and with the correct metadata available. 
Last, increasing legislation is requiring that 
information on bioactive compounds should 
be more readily available. For example, 
on 1 June 2007 the REACH (Registration, 
Evaluation, Authorisation and Restriction of 
Chemical substances) legislation came into 
force across the European Union. This legis-
lation requires that additional information on 
chemicals should be made available, depend-
ing on the quantity imported or manufac-
tured, and it has been estimated that 30,000 
chemicals may need to be re-evaluated in 
accordance with these requirements13.
It is hoped that the publication of these 
proposed standards will encourage the depo-
sition of data that fulfil the MIABE criteria 
into public databases such as ChEMBL or 
PubChem, not only by the academic com-
munity but increasingly also by companies. 
Following on from the period during which 
these guidelines were publicly available for 
feedback (see below), we also hope that 
highlighting their availability through publi-
cation will now provide the opportunity for 
broad community feedback and adaptation 
if needed. Once a stable version of these 
guidelines has been established, however, it 
is intended to make updates as infrequent 
as advances in technology will allow, thus 
providing long periods of stability to encour-
age the adoption and implementation of the 
guidelines.
MIABE: principles and process
In order to derive the maximum benefit 
from the publication of data on bioactive 
entities, it is important that key information 
is included in each paper such that the  
properties of these molecules are fully  
represented, their effects on biological 
systems (both positive and negative) are 
accurately detailed and factors that may 
contribute to the activity of the molecule 
are stated.
To this end, we brought together repre-
sentatives of life science companies, data 
resource providers and academic groups to 
develop a checklist of the information that is 
considered to be important to include with 
published data sets on bioactive entities; this 
is the minimum information that is required 
for the activity of a molecule to be both fully 
understood and compared with other mol-
ecules that either share a common chemical 
structure or a similar mechanism of action. 
Initial versions of the MIABE standard 
were produced through the Pharmaceutical 
Industry Forum hosted at the European 
Bioinformatics Institute, and were made 
available for community input through 
pre-publication on the Human Proteomics 
Organization Proteomics Standards 
Initiative (HUPO-PSI) website14 and also via 
the Minimum Information for Biological 
and Biomedical Investigations (MIBBI)  
portal (see the MIBBI portal website). 
Extensive consultation was then undertaken 
until the current version of the guide-
lines was deemed to be appropriate for 
publication.
It is intended that the MIABE guidelines 
will be adhered to by anyone planning on 
publishing papers reporting on bioactive 
entities, by the implementers of resources 
such as databases that hold this informa-
tion and by any body or institution that 
funds such discovery work and requires 
the results to be published at the end of the 
grant period. As with other similar reporting 
guidelines9, the MIABE checklist adheres to 
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the criteria of sufficiency (a reader should 
be able to understand and critically evalu-
ate the interpretation and conclusions, and 
support their experimental corroboration) 
and practicability (the guidelines should not 
be so burdensome as to prohibit their wide-
spread use).
It should be noted that the scope of this 
document is limited to data on bioactive 
entities that would be regarded either as pre-
clinical (for potential drugs) or in early-stage 
development (for other types of bioactive 
molecules); a discussion of the publica-
tion of clinical data is a subject that is more 
appropriate for a separate effort. It is also 
recognized that the full list of requirements 
described in the document covers the entire 
path taken by a molecule from synthesis to 
preclinical development as a potential drug 
(or equivalent). Such data may not be avail-
able for many compounds that fail to fulfil 
one or more of the criteria that are necessary 
for their development into a potential drug, 
or for compounds that were not gener-
ated with such a goal in mind, but all of the 
data generated on such compounds should 
appear in any publication on their activity, to 
maximize the value of these compounds as 
research tools. Similarly, data on a successful 
agent may be published in multiple papers. 
Early-stage investigations — for example, a 
report on the results of a high-throughput 
screen — may not have included studies 
that generate all of the physicochemical 
data listed in the MIABE guidelines. These 
guidelines are not intended to provide an 
additional burden to researchers by requir-
ing the generation of data merely for the sake 
of publication, but in cases in which data 
have been generated they should be fully 
and clearly reported with the appropriate 
metadata included. Finally, it should also be 
remembered that although this document 
focuses on bioactive agents, data on inactive, 
closely related analogues are often of equal 
value, and can provide negative controls and 
information for those trying to build bioac-
tivity into a particular molecular scaffold. 
Such data should also be fully reported using 
these guidelines.
Reporting requirements in MIABE
The current MIABE checklist is provided 
in TABLE 1, and details on two exemplified 
compounds from a relevant journal article15 
have been presented as a MIABE-compliant 
document in Supplementary information  
S1 (table) and Supplementary information S2  
(table). Further discussion of the aspects 
of the checklist is provided in the 
sections below.
Data formats and related initiatives. It 
has not previously been standard practice 
when reporting on bioactive molecules to 
consider data exchange formats other than 
the published paper. However, as public 
data repositories become established, the 
requirement to exchange data between 
them — or for users to download non-
redundant data sets in a common format — 
will become increasingly important. In the 
molecular interaction field, such a format 
— the HUPO PSI-Molecular Interactions 
(MI) XML 2.5 interchange format — exists 
and has been publicly available and widely 
used for several years. This format can 
capture extensive details about many types of 
interactions, including interactions between 
bioactive entities and their target molecules, 
the biological role of each molecule  
within that interaction, a detailed 
description of interacting domains and the 
kinetic parameters of the interaction16. The 
ability to describe the structure of individual 
molecules and to carry out metadata analysis 
on that molecule is also inherent to this 
format. This format is supported by data 
management and analysis tools and has 
been adopted by major interaction data 
providers and tool developers, and used 
in visualization and analytical software. In 
addition, a simpler tab-delimited format 
— MITAB2.5 — has been developed for 
the benefit of users who require only 
minimal information in an easily accessible 
configuration.
It has been suggested that supporting 
the continued development of this format, 
rather than attempting to ‘reinvent the 
wheel’, will be the most practical approach 
for fulfilling the MIABE goals. This will 
allow producers of drug–target information 
to merge their data with existing 
information in the molecular interaction 
databases and use HUPO PSI-MI XML 
2.5-compliant resources, such as Cytoscape, 
to visualize small-molecule data in 
conjunction with cellular interactomes or 
pathways. For example, by mapping much 
of its data to the HUPO PSI-MI standards 
and formats, the ChEMBL database has 
made this content available as a Proteomics 
Standard Initiative Common Query 
Interface (PSICQUIC) web service17. This 
allows users of the Reactome pathways 
database18 to query for small molecules 
that modulate a specific point in a pathway. 
Supplementary information S2 (table) 
contains the HUPO PSI-MI XML file for 
the publication15 from which the examples 
in Supplementary information S1 (table) 
were taken.
Standardization of the reporting and 
collection of data is now being encouraged 
across the biomedical field in an effort to 
improve data quality and availability. To 
manage this process, the MIBBI project (see 
the MIBBI website) has been established, 
which maintains a web-based, freely acces-
sible resource for checklist projects such 
as MIABE. MIBBI, which is managed by 
representatives of its participant communi-
ties, provides access to checklists (as well 
as complementary data formats, controlled 
vocabularies, tools and databases) and 
ensures that new efforts are not redundant 
or overlapping with an existing resource19. 
If the MIABE guidelines overlap with exist-
ing resources, the work of these resources 
is referred to, rather than repeated. For 
example, the MIABE guidelines refer to the 
Minimum Information required for report-
ing a Molecular Interaction Experiment 
(MIMIx) standard20, the Standards for 
Reporting Enzymology Data (STRENDA) 
guidelines, the Minimum Information about 
a Protein Affinity Reagent (MIAPAR) stand-
ard21 and the Minimum Information about 
a Cellular Assay (MIACA) standard. There 
are ongoing efforts at the MIBBI Foundry to 
provide a roadmap for users of all ‘Minimum 
Information’ documents, in which more 
than one checklist may be relevant to the 
information described in their publication 
or database submission, which will enable 
users to consult a single list of requirements 
instead of reading multiple documents.
Controlled vocabularies. Where possible, 
the MIABE guidelines propose using exist-
ing controlled vocabularies or ontologies 
to describe entities, processes and condi-
tions detailed within a paper. This benefits 
the reader as it reduces the possibility of 
ambiguity if a term with multiple meanings 
is used, and also aids the curation of data, 
as well as subsequent search and analy-
sis. Several such controlled vocabularies 
are available on the Open Biological and 
Biomedical Ontologies website. These con-
trolled vocabularies may be used to describe 
tissues, diseases and molecular interactions 
(including enzyme–substrate interactions). 
Shuffenhauer et al.22 carried out an early 
attempt to develop an ontology that is spe-
cific to bioactive small molecules. The exist-
ing HUPO PSI-MI controlled vocabulary14 
that is used to annotate the format described 
above has already been extended to allow for 
a full description of the properties of a bio-
active molecule, and further input into the 
development of this resource is welcomed. 
It is recommended that the HUPO PSI-MI 
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Table 1 | Minimum information about a bioactive entity
Information Notes
Responsible person or role 
Contact person; 
organization;  
contact e-mail 
The (stable) primary contact person for this data set should be provided; this could be the individual carrying out the 
experiment, the head of a laboratory or a line manager. In cases in which responsibility rests with an institutional role 
(for example, one of a number of duty officers) rather than an individual, the official name of the role rather than the 
name of an individual should be provided. In all cases, the affiliation and stable contact information should be given 
Molecule properties 
Primary name (and 
synonyms) 
Authors should select an appropriate name by which the molecule should be known — for example, the international 
nonproprietary name (INN) or research codes — but also list any synonyms that are already widely used in the public 
domain, if these are not already listed within a public domain database. If the molecule is described in a public 
database, the relevant accession number in that resource and the database name should be given. Internal compound 
designations or research codes need to be checked for homonym clashes, explicitly listed and clearly matched with 
either the corresponding public database identifier or a standard structural representation such as SMILES or InChI 
Molecule type (MI:0313) Authors should specify the molecular type of the bioactive entity: for example, whether it is a small molecule, a 
protein, an antibody, and so on. It is recommended that the terms taken from ‘interactor type’ in the HUPO PSI-MI 
controlled vocabulary are used (see the Ontology Lookup Service for further information) 
Chemical IUPAC name 
(MI:2007) 
The standard chemical name for the drug should be specified 
Chemical structure 
(MI:2009) 
An image of the structure or sequence of the molecule should be provided, as applicable. A corresponding accession 
number from an externally available resource is also acceptable (for example, ChEBI, PubChem or UniProtKB), 
provided the molecule is an exact match to the bioactive entity being described. If a molecule is a fragment or an 
engineered product of the entity that is described in the database, changes to the given structure or sequence should 
be described in full detail. For small molecules, exact details of stereochemistry should be included. If a molecule 
contains specific isotopes of an atomic element and not the natural isotope distribution, this should be stated 
Standard InChI string and 
key (MI:0970) 
The InChI and InChI key should be provided for all small molecules. The InChI string is derived from the structure of 
a compound.The InChI key is a fixed-length format that is directly derived from InChI. It is based on a strong hash 
(SHA-256) algorithm of an InChI string and allows for efficient database indexing. The programme and the version of 
the programme that has been used to generate the InChI key should be stated 
Chemical salt If different salts (for example, chloride or mesylate) of a chemical are prepared, it should be clearly stated throughout 
which salt has been used in each experiment. Other known forms of a molecule — for example, hydrates — should 
also be described 
Prodrugs If a bioactive entity has been synthesized as a prodrug, both the original and final forms of the molecule should 
be named and described as above. The route by which the molecule is metabolized to its final form should also be 
described, if this is known 
Molecule production 
Chemical synthesis and/ or 
molecule production 
The synthetic route by which a molecule, or series of molecules, has been produced should be fully described or 
referenced, if known. If the molecule is a natural product, the source, extraction method, estimated purity and yield 
should be stated. If it has been purchased, the manufacturer and product number should be stated 
Percentage purity The percentage purity of any molecule should be given and the method by which this measure has been derived 
should be briefly described 
Physicochemical properties 
Molecular weight (MI:2025) The molecular weight of the compound (clearly stating whether salt and/or water molecules are included or not) 
should be provided 
Water solubility 
(experimental) (MI:2027) 
The water solubility of the compound should be given (in mg per ml or g per l) 
LogP/hydrophobicity 
(experimental) (MI:2029) 
The logarithm of the water/octanol partition coefficient (logP) or hydrophobicity score should be given. For charged 
molecules, a logD against a defined buffer/organic phase should also be supplied*
In vitro cell-free assays‡
Name of primary target Protein nomenclature should be taken from an external resource, such as UniProtKB, or it should be widely accepted 
in the literature. Gene nomenclature should either be the approved nomenclature for that species — for example, 
from the HGNC — or it should be taken from a public domain resource such as Ensembl. Names must either be 
accompanied by an accession number from an external resource (for example, Ensembl, GeneID or UniProtKB) 
or a statement giving the species of origin of the gene and/or protein product. If the assay is directed against a 
heteromeric protein complex that is known to comprise multiple proteins, the common name of this complex should 
be used (for example, 20S proteasome or γ-secretase) 
Assay details A free-text description of the assay should be provided, giving enough information for the reader to understand 
and, if necessary, reproduce the assay conditions. This should include a clear description of the substrate, preferably 
including an accession number from an external resource such as UniProtKB or ChEBI 
Assay parameters Any parameter of the assay (for example, pH, temperature or time course) that may affect the final result should be 
described in full detail
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Information Notes
In vitro cell-free assays‡ cont.
Delivery systems A description of the solvent that is used to dissolve the test molecule (for example, DMSO), and a statement of the 
final concentration of that solvent in the assay should be given. Details of control samples should also be included
Results Where possible, results should be given as a numerical value with experimental error, rather than — or in addition 
to — a free-text description. If a derived kinetic value (for example, K
i
) is given, the method by which it was derived 
should be stated, along with any range in values observed. Values that are less dependent on assay conditions should 
be quoted by preference — for example, K
i
 values should be quoted rather than IC
50
 values
Secondary gene targets Results obtained against all possible targets should be given, even when they are negative, to give as complete a 
profile as possible when describing the activity of the bioactive agent
Cellular assays§
Cell type Details of the cell line or the source of primary cell culture should be given, such that the reader could obtain or 
prepare the same cell type. If a cell line is derived in-house, details should be given and a statement made if the cell 
line is available on request. Any change to the wild-type state of the cell — for example, the transfection of additional 
or mutated genes — should be noted
Culture conditions A full statement should be given of the culture conditions, including media, passage number and the perceived state 
of the cell at the time of the experiment
Agonists or antagonists A full description should be given of all agonists (or antagonists) added, including the concentration used, length of 
exposure of the cell to the agonist or antagonist and details of any delivery vehicle used
Results Results should be described in full detail and, where possible, accompanied by numerical values assessing the activity 
of the agent and experimental error. If a derived value is given, the method by which it was derived should be stated, 
along with any range in values observed. If a statistical assessment of the data is made, details of the method used 
should also be given
Secondary cellular assays Results obtained against all possible targets should be provided, even when they are negative, to give as complete a 
profile as possible when describing the activity of the bioactive agent
Toxicological observations If an effect of potential toxicological relevance is observed — for example, cell death — the effect and the 
concentration of the agent above which this effect was observed should be recorded
Whole-organism studies||
Animal studies For all animal studies the species, strain, sex, age and weight of the animals should be stated. Any feeding or housing 
conditions that deviate from the norm should be recorded, as should any procedure that may have caused stress 
to the animal during the course of the experiment. If an animal is anaesthetized or treated with any other agent in 
addition to the bioactive entity under investigation, full details of this agent should be recorded
Plant studies For all plant studies the species, strain and life-cycle stage of the plant should be stated. Any nutrient or housing 
conditions that deviate from the norm should be recorded, as should any procedure that may have caused stress to 
the plant during the course of the experiment. If a plant is treated with any other agent in addition to the bioactive 
entity under investigation, full details of this agent should be recorded
Fungal studies For all fungal studies the species, strain and life-cycle stage of the fungus should be stated. Any nutrient or housing 
conditions that deviate from the norm should be recorded, as should any procedure that may have caused stress to 
the fungus during the course of the experiment. If a fungus is treated with any other agent in addition to the bioactive 
entity under investigation, full details of this agent should be recorded
Disease models A full description should be given of how the disease condition was induced, including timings, drug concentrations 
and vehicles used, if appropriate. The treatment of control groups should also be described in full detail. If the 
condition that is induced is a model (or a partial model) of a disease, it should be made clear which disease (or group 
of diseases) this model is believed to represent
Dosing route The route by which a drug is delivered (for example, oral gavage) should be clearly stated
Dosing schedule Full details of any dosing schedule, including vehicle and timings, should be given. Any period of respite from the drug 
should also be recorded
Results Results should be described in full detail and, where possible, accompanied by numerical values assessing the activity 
of the agent and experimental error. If a statistical assessment is made of the data, details of the method used should 
also be given. If a series of parameters are used as the end point of the disease model, the effect of the agent on each 
parameter should be described in full detail and the statistical significance of the effect on each parameter should be 
separately calculated
Toxicological observations If a potential toxicological observation is made (pre- or post-mortem), the effect and the concentration of the agent 
above which this effect was observed should be recorded, together with experimental error. General indicators of 
animal welfare, such as changes in body weight, should be also recorded. Any change in a physiological parameter 
that is observed during a study should be noted
Drug–drug interactions All observed drug–drug interactions should be noted. The method by which these interactions were identified and 
the dosing regime and vehicle that was used for each agent should be stated
Table 1 cont. | Minimum information about a bioactive entity
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controlled vocabulary terms be used as the 
primary source of controlled vocabulary 
terms for annotating bioactive entity data, 
with additional terms sourced from addi-
tional vocabularies when required. The 
HUPO PSI-MI XML file in Supplementary 
information S2 (table) is fully annotated 
using such terms.
An ontology for the description of drug 
discovery investigations has also been pub-
lished23. Researchers may also wish to incor-
porate terms from this controlled vocabulary, 
which allows a clear definition of the various 
stages of compound progression into database 
depositions or descriptions of their work.
Molecule structure and nomenclature. The 
representation of bioactive entities in the 
literature varies in both quality and depth. In 
many publications there is an image-based 
representation of the core chemical structure, 
with substituents listed in a separate table and 
often accompanied by preliminary biologi-
cal assay data. Journals tend to recommend 
or insist upon a particular nomenclature 
system, but do not enforce this at the level of 
the individual molecule, which is often only 
described using an originator-specific identi-
fier. This makes data almost impossible to 
automatically mine, and currently this infor-
mation can only be harvested for computa-
tional searching by manual curation.
Several algorithms for information-
reduced linear notation for chemical 
structures have been developed, including 
SMILES (Simplified Molecular Input Line 
Entry Specification)24 and International 
Union of Pure and Applied Chemistry 
(IUPAC) International Chemical Identifier 
(InChI) strings or keys25 (see the IUPAC 
website), which are computationally acces-
sible but not appropriate for use in free text. 
It is recommended that the ‘standard’ InChI 
key and strings be used, as these remove 
ambiguity that could arise from user-settable 
options for tautomerism and stereochemis-
try. These are supported by the InchI Trust 
as being the most suitable algorithms for 
use in search engines and software applica-
tions. The InChI key for molecules that have 
been studied for a research paper should be 
supplied as part of the publication, either in 
the main text, supplementary material or 
in a parallel deposition in a public domain 
database.
If the molecule is synthesized as a prodrug, 
both the initial structure of the molecule and 
Information Notes
Pharmocokinetic studies¶
Absorption The methods by which drug absorption was measured must be fully described, as detailed above. This description 
should include predictive systems, such as Caco-2 cell line data, in addition to actual measurements of the compound 
in animal studies. Details of any additional experimental factors that may affect the rate of absorption — for example, 
when the drug was delivered with respect to feeding times — should also be recorded
Protein binding Estimates or measures of protein binding should be given, with appropriate experimental methodology, as detailed 
above. If an isolated protein has been used — for example, serum albumin — either an accession number or the 
species of origin of the protein should be stated. If variant data are included, variants should be accurately mapped to 
an underlying protein sequence (of a given accession number) and crossreferenced to the dbSNP, if possible
Dosing route The route by which a drug is delivered (for example, oral gavage) should be clearly stated
Dosing schedule Full details of any dosing schedule, including vehicle and timings, should be given. Any period of respite from the drug 
should also be recorded
Half-life The half-life of a drug following both single and multiple dosing should be stated, and the method by which this was 
measured and any factors that may affect this value should be recorded
V
max
The V
max
 of a drug following both single and multiple dosing should be stated, and the method by which this was 
measured and any factors that may affect this value should be recorded
Volume of distribution The volume of distribution should be calculated and quoted in litres
Bioavailability For drugs that are delivered by non-intravenous means, the percentage bioavailability should be given
Metabolism The methods by which drug metabolism was measured must be fully described, as detailed above. This description 
should include predictive systems, such as cytochrome P450-isolated enzyme data, in addition to measurements 
of the actual compound in animal studies. If an isolated protein has been used — for example, a cytochrome P450 
enzyme — either an accession number or the species of origin of the protein should be stated. If variant data are 
included, variants should be accurately mapped to an underlying protein sequence (of a given accession number) and 
crossreferenced to the dbSNP, if possible. If a compound proves to be inhibitory to a metabolizing enzyme such as a 
cytochrome P450 enzyme, these data should also be included. Details of any additional experimental factors that may 
affect the rate of metabolism — for example, when the drug was delivered with respect to feeding times — should 
also be recorded
Metabolites All observed drug metabolites should be identified, including intermediates that are further metabolized prior to 
excretion. The method by which each metabolite was identified, its concentrations and any observed changes in 
metabolite composition following repeated dosing should be observed
Excretion The excretion route of the parent compound and any identified metabolite should be identified. The rate of 
compound (and metabolite) excretion should also be given
*LogP (partition) or LogD (distribution coefficient) are the logarithms of the ratio of concentrations of a compound in the two phases of a mixture of two immiscible 
solvents at equilibrium. ‡Defined as the testing of the activity of the agent against isolated or partially purified biomolecules. §Defined as the testing of the activity 
of the agent in whole-cell systems. ||Defined as the testing of the activity of the agent in whole-organism systems. ¶Defined as a determination of the fate of 
substances that are administered externally to a living organism. ChEBI, Chemical Entities of Biological Interest; dbSNP, Single Nucleotide Polymorphism Database; 
DMSO, dimethyl sulphoxide; HGNC, HUGO Gene Nomenclature Committee; HUPO-PSI-MI, Human Proteomics Organization Proteomics Standards Initiative 
Molecular Interactions; IC
50
, half-maximal inhibitory concentration; InChI, IUPAC International Chemical Identifier; IUPAC, International Union of Pure and Applied 
Chemistry; K
i
, inhibition constant; MI, molecular interaction; SMILES, Simplified Molecular Input Line Entry Specification; UniProtKB, UniProt Knowledgebase; V
max
, 
velocity of enzyme-catalysed reaction at infinite concentration of substrate.
Table 1 cont. | Minimum information about a bioactive entity
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the final bioactive entity should be described. 
If it is known, the route by which the mol-
ecule is metabolized to its final form should 
be described. If the entity is known to have 
metabolites that themselves show in vivo 
activity, these should also be detailed. Drug 
activities, even at the research phase, are often 
influenced by the choice of counter-ion (salt) 
or vehicle (such as vegetable oils). As such, 
the testing results should include these data 
where possible, particularly in situations in 
which pharmacokinetics (for example, in 
intact animal studies) and/or absorption (for 
example, in cell-based assays) could influence 
drug concentration at the target.
As a drug progresses to the market, it is 
not uncommon for several different salts to 
be created and used in different assays, or  
for different formulations to be developed 
for marketing. To ensure that there is no 
ambiguity in the literature, the form of the 
molecule being described in the publication 
should be clearly indicated and the nomen-
clature used should be as informative and 
unambiguous as feasibly possible. If it is 
known or suspected that the molecule has 
solid-state properties that affect its behav-
iour — for example, crystal polymorphs 
— these should be described, if possible. 
In the case of known molecular structure 
heterogeneity, a representative molecular 
structure or structures should be given, 
with an accompanying explanation of the 
possible ambiguity.
Increasingly, biomolecules such as 
recombinant peptides and proteins are 
being used in medicine. Where possible, 
these molecules should be referenced to 
an external resource such as the UniProt 
Knowledgebase7 for protein sequences, but 
additional data such as the mapping of pep-
tide ligands to large precursors should also 
be provided. Similarly, the presence of tags, 
fusion proteins, post-translational modifi-
cations such as glycosylation or disulphide 
links, and synthetic modifications such as 
conjugation to polyethylene glycol (PEG) 
should be described. If the biological activ-
ity depends on a particular engineered 
form of the original sequence (for example, 
the replacement of one or more amino 
acids), this should be clearly indicated. If 
the protein in question is an antibody, the 
reader should be referred to the MIAPAR 
guidelines21 for a detailed description of 
required metadata for such molecules.
Molecule synthesis, isolation or pur-
chase. Another aim of the MIABE suite 
of documents is to enable studies to con-
firm or refute a given result. In the case 
of chemically synthesized molecules, the 
synthetic route should be given in enough 
detail for a laboratory to have a reason-
able chance of reproducing the process 
described and producing the range of 
compounds listed in the article. Similarly, 
if the molecule has been isolated from a 
particular organism or isolate, the source, 
growth conditions and purification pro-
cedure should be detailed or referenced if 
known. For all compounds, this should be 
accompanied by an indication of purity and 
identity, and the methods by which this 
has been ascertained; for example, nuclear 
magnetic resonance or mass spectrometry.
Purchased compounds should be 
described by giving the manufacturer’s 
name and the appropriate catalogue and 
batch numbers. Should the molecule 
already be in common use and fully 
described by a public resource such as 
ChEBI10 or PubChem11, an accession num-
ber will be sufficient to refer back to much 
of these data but any additional informa-
tion on subsequent confirmation of identity 
should be included.
Physicochemical properties. Physicochemical 
parameters can be qualitative and/or quanti-
tative; if they are quantitative, units should be 
given. In both cases, the experimental condi-
tions under which the data were generated 
(for example, temperature and pH) should 
be stated.
Only experimental parameters are 
included in the minimum requirements; 
however, if calculated parameters are given 
in a publication, the method by which they 
are calculated should be described.
In vitro assays. The MIABE guidelines 
describe all in vitro assays, including mech-
anism-of-action studies, studies to ascertain 
off-target activities and drug metabolism 
studies, as well as cell-free and cellular 
assays. More detailed guidelines exist in 
particular areas — such as the STRENDA 
guidelines for isolated enzyme studies and 
the MIMIx guidelines for interaction stud-
ies20 — and these should be consulted with 
the MIABE documentation. Common to 
all of these documents, however, is a clear 
requirement that both the compound and 
the target should be clearly and unambigu-
ously identified (for example, by a sequence 
database accession number), and that the 
assay method should be described in enough 
detail for researchers to both fully com-
prehend and, if appropriate, reproduce the 
conditions locally. If a series of compounds 
has been assessed for a structure–activity 
relationship, each experimental value should 
be clearly matched to the structure of the 
specific compound for which it has been 
generated. In the case of library screening, 
Inglese et al.26 have published additional 
guidelines that are complementary to the 
MIABE guidelines.
For cell-based assays, a more detailed 
list of requirements has been drawn up by 
the MIACA group (see the MIACA home-
page), which should also be consulted. It is 
important that all changes to the wild-type 
cellular proteome, such as the transfection 
of genes coding for mutated or tagged pro-
teins, are clearly documented as changes in 
protein expression patterns may affect both 
the cellular phenotype and the response to 
bioactive entities. In particular, if a protein 
is overexpressed in a recombinant cellular 
assay and is the primary focus of that assay, 
the target (or targets) should be clearly and 
unambiguously identified, as for in vitro cell-
free assays. For cellular assays in which the 
readout is a biological process for which the 
molecular pathway that is the hypothesized 
focus of the assay is well understood, the 
biological process, pathway and primary 
protein target (or targets) should be stated 
using existing controlled vocabularies such 
as the Gene Ontology27.
In vivo assays. In cases in which models are 
intended to represent a disease condition 
or a process that is common to multiple 
diseases — such as inflammation — this 
should be described as fully as possible, 
potentially by reference to a disease ontol-
ogy, such as the one available at the Disease 
Ontology Community Wiki website. If 
the assay uses a model organism that has 
undergone genetic manipulation, such as 
gene knockout or transgene insertion, and 
the behaviour of the bioactive entity is com-
pared with reference to the wild-type strain, 
the potential target (or targets) in the genet-
ically modified organism should be clearly 
identified. All observations should be fully 
reported, including pre- and post-mortem 
and subsequent analyses. In particular, data 
relating to potential off-target and toxico-
logical effects are commonly not reported, 
but hold valuable information that may aid 
the design of subsequent generations of 
bioactive molecules.
In vivo assays also have ethical considera-
tions. It is not the purpose of these guide-
lines to discuss these ethical considerations, 
which are often specific to the country of 
the originating research facility. Publication 
requirements with regard to ethical consid-
erations are also provided by journals.
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Mechanism-of-action studies. Other studies 
that contribute to the understanding of the 
mechanism of action of a particular mol-
ecule should be reported using the appropri-
ate part (or parts) of the MIABE guidelines. 
Such data could include the stoichiometry 
of binding or the mechanism by which the 
compound binds to its target.
Pharmacokinetic studies. In cases in which 
pharmacokinetic studies have been carried 
out, they should be reported in full detail. 
Calculated or predicted data should be 
clearly differentiated from experimentally 
verified data, and any algorithms that were 
used to determine the calculated values 
should be described.
Biomarkers. During the past decade, various 
biomarkers — for example, levels of specific 
plasma proteins or microarray expression 
profiles — of disease processes and drug 
responses have been increasingly investi-
gated in preclinical and clinical studies of 
potential drugs. For example, in preclini-
cal studies such biomarkers may be used 
to aid the selection of the best candidate 
compounds to advance to clinical trials, 
and in the clinic they can be used to stratify 
patients with subtypes of a disease based on 
their likelihood of responding to a particular 
drug. If biomarker studies are included, they 
should conform to the same standards as 
any other bioactive entity, and be fully and 
unambiguously described. As the amount of 
data in this area increases and compounds 
move into preclinical and clinical develop-
ment, it will be necessary to revisit and 
update existing standards to ensure that 
these data can be fully described.
Conclusion
The main aim of the MIABE document is to 
support the core informatics-related aspects 
of the long-term bioactive molecule discov-
ery process, ensuring that the data generated 
from previous expensive and time-consum-
ing projects are not lost but can be harvested 
and built on in the future. By following such 
guidelines, authors can produce a useful, 
richly annotated data set about the molecule 
or series of molecules that they are describ-
ing, which will allow effective data retrieval 
by anyone wishing to reproduce or analyse 
the results, or undertake comparative and/or 
predictive studies.
The publication of the MIABE guidelines 
is recognized by the authors of this article 
as being only a first step in the long process 
of making all data on bioactive molecules 
readily available in a single common format, 
with full and consistent data description. Key 
challenges in achieving this goal will initially 
include the spreading of this message to the 
widely disparate group of workers in this field, 
some of whom have commercial interests that 
constrain their data exchange policies and 
format usage. Finding a single professional 
body to represent this group has also proved 
to be an issue, and as a result existing stand-
ards bodies have been utilized to supply an 
independent platform from which to launch 
this standard. These bodies will also be 
important in maintaining the MIABE check-
list, to incorporate new technologies and 
advances into the procedure (see BOX 1). The 
endorsement and adoption of this standard by 
public database resources will also be crucial, 
and many such resources have had a key role 
in developing the MIABE checklist so far.
It is hoped that more groups will recognize 
the value of putting such data into the public 
domain to become part of an ever-increasing 
knowledge bank on bioactive molecules. 
This would aid the development of improved 
Box 1 | Frequently asked questions about MIABE
Below we clarify common questions about using and contributing to the Minimum Information 
about a Bioactive Entity (MIABE) guidelines.
What is MIABE and what is it for?
•	MIABE is a formal list of the items of information that should be provided when describing the 
synthesis and subsequent analysis of any potentially bioactive entity (a molecule that is designed 
to show activity in a biological assay)
•	MIABE is a checklist of all the information that should support the description of each compound 
in either a journal article or database submission. Although it is acknowledged that some data 
may only be available though reference to an earlier article, or a compound may not have 
completed a full evaluation, if such data are available they should be MIABE-compliant
How does MIABE differ from the ‘guidelines to authors’ provided by journals?
•	Compared with standard author guidance, the MIABE guidelines are much more specific. The 
guidelines explicitly list every piece of information that should be provided, leaving nothing open 
to interpretation
•	The MIABE checklist does not address data quality in any form; such judgments are the province 
of reviewers (who will be better equipped to form such judgments if they are provided with a 
MIABE-compliant data set)
•	The MIABE checklist does not recommend the use of any particular protocol and only requests 
that each protocol is described in full detail
What tools are available to enable me to use MIABE?
Normally, the MIABE guidelines would be consulted as a manuscript is being prepared, and 
compliance requires no dedicated tool. However, if you wish to prepare a database submission or 
use existing data in a database, several tools are available, including:
•	Dedicated controlled vocabularies such as the Human Proteomics Organization Proteomics 
Standards Initiative-Molecular Interactions (HUPO PSI-MI) controlled vocabulary to enable data 
annotation
•	Both XML and MITAB (tab-delineated) schemas in which data can be downloaded from one 
resource and moved into a second. The use of such formats enables the merging of separate  
data sets, including with protein interaction networks or pathway data, and enables access to 
additional visualization and analysis tools such as Cytoscape
•	A common web service (the Proteomics Standard Initiative Common Query Interface; 
PSICQUIC), which enables data search over multiple resources
How can I have input into future versions of MIABE?
Although it is our intention to keep all modules stable for as long as possible (at least one year per 
version), updates and extensions will be required as new techniques are developed and existing 
ones evolve. The MIABE guidelines can be accessed through the Minimum Information for 
Biological and Biomedical Investigations (MIBBI) website and contact e-mails will be maintained. 
The module has been developed, in part, by the Molecular Interactions workgroup of the 
HUPO-PSI-MI worktrack, which has an annual Spring workshop that is open to anyone to attend, 
plenary meetings at the HUPO congress, a mailing list and regular phone conferences on data 
formats and controlled vocabulary updates.
We also intend to regularly review the MIABE standard through the European Bioinformatics 
Institute (EBI) Industry Programme — which is a forum for interaction between the European 
Molecular Biology Laboratory (EMBL)-EBI and the industrial life science research sector — and to 
further disseminate its message through the small and medium-sized enterprise (SME) Support 
Forum meetings (see the EBI Industry Programme website). Discussions are also welcome on the 
ChEMBL-og website.
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molecules with a well-understood mode of 
action, high safety and environmental com-
patibility to target an expanded druggable 
genome in an increasing number of species.
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